The Future for Genomic Medicine in Inflammatory Diseases

Author(s):  
Chris Kitson
Author(s):  
Madhav Bhatia

Inflammation is an adaptive response to injury, but uncontrolled inflammation can lead to tissue damage and disease. Research in our laboratory (since confirmed in different laboratories worldwide) has shown that hydrogen sulfide (H2S) acts as a mediator of inflammation in different disease conditions. Learning about a novel mediator of inflammation results in unique opportunities with which to approach inflammatory diseases. At the same time, the complexity of biological systems and translation of research from the bed to the bedside also presents challenges. This Editorial aims to discuss the opportunities and challenges in relation to the role of H2S in inflammation, and the future prospects for this research.


2019 ◽  
Vol 28 (2) ◽  
pp. 438-448
Author(s):  
Kelly M. East ◽  
Meagan Cochran ◽  
Whitley V. Kelley ◽  
Veronica Greve ◽  
Kristina Emmerson ◽  
...  
Keyword(s):  

2018 ◽  
Vol 50 (8) ◽  
pp. 563-579 ◽  
Author(s):  
Jeremy W. Prokop ◽  
Thomas May ◽  
Kim Strong ◽  
Stephanie M. Bilinovich ◽  
Caleb Bupp ◽  
...  

Genomic sequencing has undergone massive expansion in the past 10 yr, from a rarely used research tool into an approach that has broad applications in a clinical setting. From rare disease to cancer, genomics is transforming our knowledge of biology. The transition from targeted gene sequencing, to whole exome sequencing, to whole genome sequencing has only been made possible due to rapid advancements in technologies and informatics that have plummeted the cost per base of DNA sequencing and analysis. The tools of genomics have resolved the etiology of disease for previously undiagnosable conditions, identified cancer driver gene variants, and have impacted the understanding of pathophysiology for many diseases. However, this expansion of use has also highlighted research’s current voids in knowledge. The lack of precise animal models for gene-to-function association, lack of tools for analysis of genomic structural changes, skew in populations used for genetic studies, publication biases, and the “Unknown Proteome” all contribute to voids needing filled for genomics to work in a fast-paced clinical setting. The future will hold the tools to fill in these voids, with new data sets and the continual development of new technologies allowing for expansion of genomic medicine, ushering in the days to come for precision medicine. In this review we highlight these and other points in hopes of advancing and guiding precision medicine into the future for optimal success.


2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Geoffrey H Siwo ◽  
Scott M Williams ◽  
Jason H Moore

2020 ◽  
Vol 109 (9) ◽  
pp. 1732-1734
Author(s):  
Hiroyuki Mano
Keyword(s):  

Author(s):  
Stephanie Clare Roth

Genomic medicine is rapidly changing the future of medicine. Medical librarians need to understand this field of research and keep current with its latest advancements. Even if they are not directly involved in genomic medicine, librarians can play an integral role by helping health care consumers and practitioners who may also need to expand their knowledge in this area. This article provides a basic introduction to genomic medicine, gives a brief overview of its recent advancements, and briefly describes some of the ethical, legal, and social implications of this emerging area of research and practice.


2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Monireh Golpour ◽  
Pouya Vatanpour ◽  
Mina Amini ◽  
Majid Saeedi ◽  
Nasim Hafezi ◽  
...  

Background. Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. Objective. Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. Methods. Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. Results. The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. Conclusion. Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly.


2019 ◽  
Vol 14 (2) ◽  
pp. 169-186 ◽  
Author(s):  
Ian D. Gray ◽  
Andrea R. Kross ◽  
Melanie E. Renfrew ◽  
Paul Wood

Precision medicine has captured the imagination of the medical community with visions of therapies precisely targeted to the specific individual’s genetic, biological, social, and environmental profile. However, in practice it has become synonymous with genomic medicine. As such its successes have been limited, with poor predictive or clinical value for the majority of people. It adds little to lifestyle medicine, other than in establishing why a healthy lifestyle is effective in combatting chronic disease. The challenge of lifestyle medicine remains getting people to actually adopt, sustain, and naturalize a healthy lifestyle, and this will require an approach that treats the patient as a person with individual needs and providing them with suitable types of support. The future of lifestyle medicine is holistic and person-centered rather than technological.


Sign in / Sign up

Export Citation Format

Share Document